The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum

Reading Rheum

September 1, 2007 • By Gail C. Davis, RN, EdD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Pain in RA

Transdermal Fentanyl for Treating Pain in RA

Berliner MN, Giesecke T, Bornhövd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Clin J Pain. 2007;23:530-534.

You Might Also Like
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
Explore This Issue
September 2007
Also By This Author
  • Reduce the Danger of Falls

Abstract

Objectives: The purpose of the study was to investigate the effectiveness and tolerability of transdermal fentanyl in a treatment regimen in patients with RA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: Two hundred twenty-six patients (mean age 66) with severe pain caused by RA who had not previously been treated with transdermal fentanyl were included in this prospective, open-label study. Pain intensity, functional impairment, and well-being were documented prospectively for 30 days after treatment with transdermal fentanyl had been initiated. Patients evaluated pain on an 11-point numerical rating scale. Quality of sleep, daily and social functioning, and treatment satisfaction were rated using 5-point categorical rating scales. General well-being was assessed by the Marburg questionnaire.

Results: Adding transdermal fentanyl to the ongoing RA therapy reduced pain intensity significantly from 8.0 (7.82 to 8.18) to 4.0 (3.75 to 4.25). Mean functional impairment due to pain also decreased significantly from “severe” at the beginning to “mild to moderate.” Treatment with transdermal fentanyl also led to a significant improvement by approximately 1.5 units for all items in the Marburg questionnaire on general well-being. At the end of the study, nearly all patients were satisfied with the pain treatment. Transdermal fentanyl was generally well tolerated. The most frequent side effects were nausea (9.7%) and vomiting (7.1%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Discussion: Patients with pain caused by RA improved in terms of pain intensity, sleep, function, and general well-being when transdermal fentanyl was added to the treatment regimen. Treatment satisfaction was high. Transdermal fentanyl also demonstrated good tolerability over a period of 30 days.

Commentary

Pain is a common symptom in RA, and many of those affected experience severe pain. Other common issues include sleep disturbance, activity impairment, and a decreased sense of well-being. The purpose of the study was to determine the effectiveness of transdermal fentanyl for reducing pain intensity and functional impairment and increasing feelings of well-being. Transdermal fentanyl continuously delivers fentanyl, a synthetic narcotic, through a patch applied to the upper torso; the patch is changed every 72 hours. While the dose varies with the individual, the generalized base recommended for all individuals as they begin treatment is 25 µg per hour (equivalent to approximately 2.5 mg of morphine/hour). This base dose can be raised by 25 µg per hour every 72 hours as needed, with recognition that 12 to 24 hours is required to reach peak plasma concentration and up to a week is needed to reach steady-state levels.1

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: Fentanyl, Pain, Patients, Research, Rheumatoid arthritisIssue: September 2007

You Might Also Like:
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.